193 related articles for article (PubMed ID: 17477516)
1. Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.
Giblin GM; O'Shaughnessy CT; Naylor A; Mitchell WL; Eatherton AJ; Slingsby BP; Rawlings DA; Goldsmith P; Brown AJ; Haslam CP; Clayton NM; Wilson AW; Chessell IP; Wittington AR; Green R
J Med Chem; 2007 May; 50(11):2597-600. PubMed ID: 17477516
[TBL] [Abstract][Full Text] [Related]
2. Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.
Chu GH; Saeui CT; Worm K; Weaver DG; Goodman AJ; Broadrup RL; Cassel JA; DeHaven RN; LaBuda CJ; Koblish M; Brogdon B; Smith S; Le Bourdonnec B; Dolle RE
Bioorg Med Chem Lett; 2009 Oct; 19(20):5931-5. PubMed ID: 19736007
[TBL] [Abstract][Full Text] [Related]
3. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
Dziadulewicz EK; Bevan SJ; Brain CT; Coote PR; Culshaw AJ; Davis AJ; Edwards LJ; Fisher AJ; Fox AJ; Gentry C; Groarke A; Hart TW; Huber W; James IF; Kesingland A; La Vecchia L; Loong Y; Lyothier I; McNair K; O'Farrell C; Peacock M; Portmann R; Schopfer U; Yaqoob M; Zadrobilek J
J Med Chem; 2007 Aug; 50(16):3851-6. PubMed ID: 17630726
[TBL] [Abstract][Full Text] [Related]
4. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
[TBL] [Abstract][Full Text] [Related]
5. Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.
Manley PJ; Zartman A; Paone DV; Burgey CS; Henze DA; Della Penna K; Desai R; Leitl MD; Lemaire W; White RB; Yeh S; Urban MO; Kane SA; Hartman GD; Bilodeau MT; Trotter BW
Bioorg Med Chem Lett; 2011 Apr; 21(8):2359-64. PubMed ID: 21420857
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
Diaz P; Xu J; Astruc-Diaz F; Pan HM; Brown DL; Naguib M
J Med Chem; 2008 Aug; 51(16):4932-47. PubMed ID: 18666769
[TBL] [Abstract][Full Text] [Related]
7. N-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamides as a novel class of cannabinoid receptors agonists with low CNS penetration.
Wei Z; Yang H; Liu Z; Tremblay M; Johnstone S; Béha S; Yue SY; Srivastava S; Tomaszewski MJ; Brown W; Walpole C; St-Onge S; Lessard E; Archambault AJ; Groblewski T; Pagé D
Bioorg Med Chem Lett; 2012 Jun; 22(12):3884-9. PubMed ID: 22607668
[TBL] [Abstract][Full Text] [Related]
8. Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).
Le Bourdonnec B; Windh RT; Ajello CW; Leister LK; Gu M; Chu GH; Tuthill PA; Barker WM; Koblish M; Wiant DD; Graczyk TM; Belanger S; Cassel JA; Feschenko MS; Brogdon BL; Smith SA; Christ DD; Derelanko MJ; Kutz S; Little PJ; DeHaven RN; DeHaven-Hudkins DL; Dolle RE
J Med Chem; 2008 Oct; 51(19):5893-6. PubMed ID: 18788723
[TBL] [Abstract][Full Text] [Related]
9. Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties.
Wang HL; Katon J; Balan C; Bannon AW; Bernard C; Doherty EM; Dominguez C; Gavva NR; Gore V; Ma V; Nishimura N; Surapaneni S; Tang P; Tamir R; Thiel O; Treanor JJ; Norman MH
J Med Chem; 2007 Jul; 50(15):3528-39. PubMed ID: 17585751
[TBL] [Abstract][Full Text] [Related]
10. Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate.
Doherty EM; Fotsch C; Bannon AW; Bo Y; Chen N; Dominguez C; Falsey J; Gavva NR; Katon J; Nixey T; Ognyanov VI; Pettus L; Rzasa RM; Stec M; Surapaneni S; Tamir R; Zhu J; Treanor JJ; Norman MH
J Med Chem; 2007 Jul; 50(15):3515-27. PubMed ID: 17585750
[TBL] [Abstract][Full Text] [Related]
11. Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.
Mitchell WL; Giblin GM; Naylor A; Eatherton AJ; Slingsby BP; Rawlings AD; Jandu KS; Haslam CP; Brown AJ; Goldsmith P; Clayton NM; Wilson AW; Chessell IP; Green RH; Whittington AR; Wall ID
Bioorg Med Chem Lett; 2009 Jan; 19(1):259-63. PubMed ID: 19010671
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of 3-amino-6-aryl-pyridazines as selective CB(2) agonists for the treatment of inflammatory pain.
Gleave RJ; Beswick PJ; Brown AJ; Giblin GM; Goldsmith P; Haslam CP; Mitchell WL; Nicholson NH; Page LW; Patel S; Roomans S; Slingsby BP; Swarbrick ME
Bioorg Med Chem Lett; 2010 Jan; 20(2):465-8. PubMed ID: 20005703
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.
Liverton NJ; Bednar RA; Bednar B; Butcher JW; Claiborne CF; Claremon DA; Cunningham M; DiLella AG; Gaul SL; Libby BE; Lyle EA; Lynch JJ; McCauley JA; Mosser SD; Nguyen KT; Stump GL; Sun H; Wang H; Yergey J; Koblan KS
J Med Chem; 2007 Feb; 50(4):807-19. PubMed ID: 17249648
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain.
Giblin GM; Billinton A; Briggs M; Brown AJ; Chessell IP; Clayton NM; Eatherton AJ; Goldsmith P; Haslam C; Johnson MR; Mitchell WL; Naylor A; Perboni A; Slingsby BP; Wilson AW
J Med Chem; 2009 Oct; 52(19):5785-8. PubMed ID: 19743867
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalen-4-carboxamides as potent and selective CB2 receptor agonists.
Han S; Thoresen L; Zhu X; Narayanan S; Jung JK; Strah-Pleynet S; Decaire M; Choi K; Xiong Y; Yue D; Semple G; Thatte J; Solomon M; Fu L; Whelan K; Al-Shamma H; Gatlin J; Chen R; Dang H; Pride C; Gaidarov I; Unett DJ; Behan DP; Sadeque A; Usmani KA; Chen C; Edwards J; Morgan M; Jones RM
Bioorg Med Chem Lett; 2015 Jan; 25(2):322-6. PubMed ID: 25488844
[TBL] [Abstract][Full Text] [Related]
16. Morpholine containing CB2 selective agonists.
Zindell R; Riether D; Bosanac T; Berry A; Gemkow MJ; Ebneth A; Löbbe S; Raymond EL; Thome D; Shih DT; Thomson D
Bioorg Med Chem Lett; 2009 Mar; 19(6):1604-9. PubMed ID: 19243942
[TBL] [Abstract][Full Text] [Related]
17. Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
Yan L; Huo P; Debenham JS; Madsen-Duggan CB; Lao J; Chen RZ; Xiao JC; Shen CP; Stribling DS; Shearman LP; Strack AM; Tsou N; Ball RG; Wang J; Tong X; Bateman TJ; Reddy VB; Fong TM; Hale JJ
J Med Chem; 2010 May; 53(10):4028-37. PubMed ID: 20423086
[TBL] [Abstract][Full Text] [Related]
18. Discovery and optimization of novel purines as potent and selective CB2 agonists.
Hollinshead SP; Astles PC; Chambers MG; Johnson MP; Palmer J; Tidwell MW
Bioorg Med Chem Lett; 2012 Aug; 22(15):4962-6. PubMed ID: 22765893
[TBL] [Abstract][Full Text] [Related]
19. Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists.
Worm K; Weaver DG; Green RC; Saeui CT; Dulay DM; Barker WM; Cassel JA; Stabley GJ; DeHaven RN; LaBuda CJ; Koblish M; Brogdon BL; Smith SA; Dolle RE
Bioorg Med Chem Lett; 2009 Sep; 19(17):5004-8. PubMed ID: 19646869
[TBL] [Abstract][Full Text] [Related]
20. Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stability.
Sellitto I; Le Bourdonnec B; Worm K; Goodman A; Savolainen MA; Chu GH; Ajello CW; Saeui CT; Leister LK; Cassel JA; Dehaven RN; Labuda CJ; Koblish M; Little PJ; Brogdon BL; Smith SA; Dolle RE
Bioorg Med Chem Lett; 2010 Jan; 20(1):387-91. PubMed ID: 19919895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
